BD1 Pipeline, page-3

From Stock head:

“We think we have been substantially undervalued, and the market is finally recognising our value,” she said.

The company is focused on early cancer detection through simple, cost-effective blood tests that could save lives.

“Our multi-product pipeline covers some of the world’s most common and deadliest cancers in multi-billion dollar markets for ovarian, breast, prostate, and pancreatic cancers,” Dr Hinch wrote in an email.

Bard1 has a number of potential value inflection points coming up, including registering its hTERT cancer blood test in South Korea this quarter, and launching its exosome purification platform next quarter.

“We’ve got a lot going on as a business, it’s going be an exciting year for Bard1 and shareholders,” Dr Hinch said.